Form 4: Halozyme Therapeutics Director Sells 10,000 Shares Under 10b5-1 Trading Plan

Jeffrey William Henderson, a director at Halozyme Therapeutics, sold 10,000 shares of common stock at an average price of $50.006 per share on January 6, 2025, under a pre-arranged trading plan.

Summary

• On January 6, 2025, Jeffrey William Henderson, a director of Halozyme Therapeutics, sold 10,000 shares of the company's common stock.
• The sale was executed under a pre-arranged trading plan adopted on September 17, 2024, in accordance with Rule 10b5-1.
• The shares were sold at prices ranging from $50.00 to $50.11, with a weighted average sales price of $50.006.
• Following the transaction, Henderson directly owns 43,611 shares of Halozyme Therapeutics.
• The reporting person will provide information regarding the number of shares sold at each price within the range upon request to the issuer, any security holder of the issuer, or the SEC staff.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by insiders are a normal part of corporate activity. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on any specific inside information at the time of the transaction.

Stakeholder Impact

• The stock sale by a director could be perceived neutrally or slightly negatively by shareholders, depending on their interpretation of the director's motives.

Key Dates